The Conversation (0)
Chart
Detailed Quote
Graybug Vision Inc is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve. The company's products under pipeline are GB-102, for the treatment of wet age-related macular degeneration, or wet AMD, and diabetic macular edema, or DME; GB-103; and GB-401.
Featured Articles and Interviews
Press Releases
See More Press Releases
Alert Options
No alert set
INN Article Notification
Alert Option
You will be notified when this event occurs. No additional settings needed.